Somewhat Positive News Coverage Somewhat Unlikely to Affect Athersys (ATHX) Share Price

News headlines about Athersys (NASDAQ:ATHX) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Athersys earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 44.8298257777222 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Athersys (NASDAQ:ATHX) traded up $0.05 during midday trading on Thursday, hitting $1.70. The company had a trading volume of 875,000 shares, compared to its average volume of 1,019,019. Athersys has a 1 year low of $1.02 and a 1 year high of $2.63.

ATHX has been the subject of several research reports. ValuEngine cut Athersys from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th. Maxim Group set a $12.00 target price on Athersys and gave the stock a “buy” rating in a report on Thursday, October 5th. Finally, Zacks Investment Research upgraded Athersys from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a report on Thursday, September 7th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $7.17.

In related news, EVP John J. Harrington sold 15,000 shares of the company’s stock in a transaction on Monday, September 18th. The stock was sold at an average price of $2.17, for a total transaction of $32,550.00. Following the completion of the sale, the executive vice president now directly owns 679,416 shares in the company, valued at approximately $1,474,332.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 9.40% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Athersys (ATHX) Share Price” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

What are top analysts saying about Athersys? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Athersys and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit